Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Enanta Pharmaceuticals Inc (ENTA)  
$7.56 0.06 (0.8%) as of 4:30 Mon 6/30


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 25,190,000
Market Cap: 190.44(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $4.26 - $16.54
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    : 8.5
Insider 3/6 Months : 9.1
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Enanta Pharmaceuticals is a biotechnology company that discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Co.'s wholly-owned research and development programs are in virology, namely respiratory syncytial virus, hepatitis B virus, severe acute respiratory syndrome coronavirus 2, and human metapneumovirus. Two protease inhibitors developed through Co.'s Collaborative Development and License Agreement with AbbVie Inc. (AbbVie) have been clinically tested, manufactured, and commercialized by AbbVie as part of its combination regimens for hepatitis C virus. Co. also develops Farnesoid X receptor agonists for NASH.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 45,000 45,000 45,000
Total Buy Value $0 $256,050 $256,050 $256,050
Total People Bought 0 1 1 1
Total Buy Transactions 0 1 1 1
Total Shares Sold 0 0 27,701 69,512
Total Sell Value $0 $0 $317,740 $732,199
Total People Sold 0 0 6 8
Total Sell Transactions 0 0 9 18
End Date 2025-03-30 2024-12-27 2024-06-28 2023-06-29

   
Records found: 296
  Page 1 of 12  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Mellett Paul J Chief Fin. & Admin Officer   •       –      –    2025-02-12 4 D $5.59 $18,592 D/D (3,326) 95,884     -
   Mellett Paul J Chief Fin. & Admin Officer   •       –      –    2025-02-12 4 A $0.00 $0 D/D 7,500 99,210     -
   Or Yat Sun Chief Scientific Officer   •       –      –    2025-02-12 4 D $5.59 $24,171 D/D (4,324) 374,535     -
   Or Yat Sun Chief Scientific Officer   •       –      –    2025-02-12 4 A $0.00 $0 D/D 9,750 378,859     -
   Luu Brendan Chief Business Officer   •       –      –    2025-02-12 4 D $5.59 $18,592 D/D (3,326) 40,221     -
   Luu Brendan Chief Business Officer   •       –      –    2025-02-12 4 A $0.00 $0 D/D 7,500 43,547     -
   Rottinghaus Scott T. Chief Medical Officer   •       –      –    2025-02-12 4 D $5.59 $15,993 D/D (2,861) 24,807     -
   Rottinghaus Scott T. Chief Medical Officer   •       –      –    2025-02-12 4 A $0.00 $0 D/D 9,750 27,668     -
   Luly Jay R. President and CEO   •       •      –    2025-02-12 4 D $5.59 $41,836 D/D (7,484) 864,654     -
   Luly Jay R. President and CEO   •       •      –    2025-02-12 4 A $0.00 $0 D/D 25,500 872,138     -
   Kieffer Tara Lynn Chief Product Strategy Officer   •       –      –    2025-02-12 4 D $5.59 $18,592 D/D (3,326) 33,479     -
   Kieffer Tara Lynn Chief Product Strategy Officer   •       –      –    2025-02-12 4 A $0.00 $0 D/D 7,500 36,805     -
   Luly Jay R. President and CEO   •       •      –    2025-02-12 4 B $5.69 $256,050 D/D 45,000 846,638 2.81 25%     
   Luu Brendan Chief Business Officer   •       –      –    2024-12-06 4 S $8.06 $18,401 D/D (2,283) 36,047 35%     
   Mellett Paul J Chief Fin. & Admin Officer   •       –      –    2024-12-06 4 S $8.06 $20,883 D/D (2,591) 91,710 35%     
   Rottinghaus Scott T. Chief Medical Officer   •       –      –    2024-12-06 4 S $8.06 $6,980 D/D (866) 17,918 35%     
   Kieffer Tara Lynn Chief Product Strategy Officer   •       –      –    2024-12-06 4 S $8.06 $18,401 D/D (2,283) 29,305 35%     
   Or Yat Sun Chief Scientific Officer   •       –      –    2024-12-06 4 S $8.06 $20,883 D/D (2,591) 369,109 35%     
   Luly Jay R. President and CEO   •       •      –    2024-12-06 4 S $8.06 $41,445 D/D (5,142) 801,638 35%     
   Or Yat Sun Chief Scientific Officer   •       –      –    2024-12-01 4 D $8.60 $13,717 D/D (1,595) 371,700     -
   Mellett Paul J Chief Fin. & Admin Officer   •       –      –    2024-12-01 4 D $8.60 $13,717 D/D (1,595) 94,301     -
   Luly Jay R. President and CEO   •       •      –    2024-12-01 4 D $8.60 $32,929 D/D (3,829) 806,780     -
   Luu Brendan Chief Business Officer   •       –      –    2024-12-01 4 D $8.60 $6,476 D/D (753) 38,330     -
   Kieffer Tara Lynn Chief Product Strategy Officer   •       –      –    2024-12-01 4 D $8.60 $6,476 D/D (753) 31,588     -
   Rottinghaus Scott T. Chief Medical Officer   •       –      –    2024-08-08 4 D $12.73 $18,662 D/D (1,466) 18,784     -

  296 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 12
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed